Skip to main content
MyDeficiencies

Eletriptan

Also sold as Relpax.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Eletriptan has no classical drug-nutrient depletion machinery. Per its FDA label, it is a CYP3A4 substrate, not an inducer ("unlikely to cause clinically important drug interactions mediated by these enzymes" at recommended doses); about 90% of its clearance is nonrenal, with no significant change in clearance across mild, moderate, or severe renal impairment; and the label documents no chelation, gastric-acid-dependent absorption, bile-acid-sequestration, renal-tubular-wasting, antidiuretic-hormone, or antimicrobial/microbiome-disrupting mechanism. It is also used acutely and intermittently for migraine attacks (maximum two doses in 24 hours), not as a chronic daily medication, which further limits the plausibility of any cumulative nutrient depletion even where a theoretical mechanism might exist. Across both classical nutrients and the seven required physiological categories, no entry in this dossier qualifies for red or orange, and both tiers are printed empty below with the reasoning, per protocol.

ATC N02CC06 · also sold as Relpax · reviewed 2026-10-01. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Eletriptan in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Magnesium - migraine-disease context flag, not an eletriptan effect

Yellow — Low

See study details

Migraine itself is associated with lower brain and cerebrospinal-fluid magnesium between attacks; no evidence found ties this to eletriptan.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The same source flags its own evidence as hard to pin down functionally: "It is challenging to measure magnesium levels accurately, as levels in the bloodstream may represent only 2% of total body stores" - relevant to Hard Rule 3 (an unfalsifiable claim needs a named, moving functional marker, which is not established here).
  • At-risk subgroups: Migraineurs generally, per the cited resource - not an eletriptan-specific subgroup, and not distinguished by which acute medication, if any, a patient uses.
  • Counter-evidence on record: No study was located measuring magnesium status before versus after eletriptan initiation. That absence is itself the operative finding here: there is disease-association evidence, but zero drug-attribution evidence.

Regulatory status

Not listed as an interaction, adverse effect, or depletion risk anywhere in the RELPAX FDA label.

Population evidence

American Migraine Foundation resource: "Studies of migraineurs have found low levels of brain and spinal fluid magnesium in between migraine attacks," proposed to arise from "decreased absorption of it in food, a genetic tendency to low brain magnesium, or from excreting it from the body to a greater degree than non-migraineurs" - three mechanisms, all intrinsic to the migraine patient, none linked to any medication.

Mechanism

Disease-intrinsic only (see above). No present mechanism was identified in the Step 2 screen by which eletriptan itself would alter magnesium status: it is not an enzyme inducer, is not renally wasted, and has no documented GI or renal-tubular magnesium interaction.

Counter-evidence held on record

This is a migraine-disease association, not an eletriptan effect. Confounding by indication is presumed per Hard Rule 6: the cited magnesium signal exists in migraineurs independent of which treatment they use, so it must never be presented to a reader as "eletriptan depletes magnesium." No supplementation dose is recommended on the basis of this entry.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden - migraine-disease context flag, not an eletriptan effect

Yellow — Low

See study details

Mitochondrial energy deficit is described as intrinsic to migraine pathophysiology; no eletriptan-specific mitochondrial data was located.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The cited review explicitly states no triptan-level data exists: "no discussion exists regarding triptans, eletriptan, or any migraine-specific medications affecting mitochondrial function" in that review's treatment of acute/preventive drugs.
  • At-risk subgroups: Migraineurs generally (disease population), not an eletriptan-specific subgroup.
  • Counter-evidence on record: No study measuring mitochondrial markers before versus after eletriptan exposure was located in this review.

Regulatory status

Not addressed anywhere in the RELPAX label.

Population evidence

Narrative review (Antioxidants/MDPI, 2025) on CoQ10 in migraine therapy: "mitochondrial energy is deficient in the brain when dealing with migraines," linking mutations in ion-channel genes (CACNA1A, ATP1A2, SCN1A) to disrupted neuronal energy metabolism in migraine.

Mechanism

Disease-intrinsic (ion-channel/calcium-flux dysregulation in migraineurs), not drug-related. No mitochondrial-pathway mechanism was identified for eletriptan itself in Step 1/2: it is cleared via CYP3A4-mediated hepatic metabolism with no documented mitochondrial toxicity signal of any kind.

Counter-evidence held on record

This entry documents the disease pathophysiology researchers cite to justify CoQ10 or riboflavin as migraine- prevention supplements. It is not evidence that eletriptan harms mitochondria, and no supplementation dose is recommended on this basis. See the Overlap map: this entry shares its single source with Oxidative stress and ATP production below.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress - migraine-disease context flag, not an eletriptan effect

Yellow — Low

See study details

Elevated oxidative-stress markers are reported in migraine patients and fall with CoQ10 supplementation in one small study; no eletriptan-specific oxidative-stress data was located.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: The review provides zero medication-level (triptan-class) redox data; its citations for the MDA/TAC finding concern supplementation, not any migraine drug.
  • At-risk subgroups: Migraineurs generally, not an eletriptan-specific subgroup.
  • Counter-evidence on record: No pre/post-eletriptan redox-marker study was located in this review.

Regulatory status

Not addressed in the RELPAX label.

Population evidence

Same 2025 narrative review: a cited study found "a decrease in oxidative stress level markers - MDA and TAC - following CoQ10 supplementation in migraine patients," implying elevated baseline oxidative stress in migraineurs; lactate, "a marker of mitochondrial metabolic disorders," was reported to correlate with headache severity in the same body of work.

Mechanism

Disease-intrinsic; eletriptan's labeled metabolism (CYP3A4 substrate, no enzyme induction, no documented mitochondrial-pathway involvement) gives no present mechanism for the drug itself to raise oxidative stress.

Counter-evidence held on record

Disease-intrinsic, not drug-caused; no supplementation dose is recommended on this basis. Shares its single source with Mitochondrial burden and ATP production - see Overlap map.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No eletriptan-specific or defensible class-level evidence, and no circulating claim to rebut, reconfirmed and broadened on a 2026-10-01 repair pass.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Both conditions for ungraded remain met after this repair pass: no Tier B/C evidence was located to support even a yellow grade, and no circulating consumer claim linking eletriptan or triptans to copper status was found (a consumer drug-induced-nutrient-deficiency resource checked in this review does not mention triptans at all - see Fails verification). No mechanism from the Step 2 screen (absorption interference, enzyme induction, renal wasting, cofactor antagonism, dilutional disturbance, microbiome disruption, intake change, or increased utilization) implicates copper for this drug. Assessment: now a better-confirmed gap than the original review's, since this pass additionally closed off the class-level extrapolation route (below), not only the drug-specific one.

Channels tried, repair pass 2026-10-01

Crossref API (the one channel that responded this pass): query "eletriptan copper" returned five results, all pharmacopeial/regulatory monographs (USP eletriptan hydrobromide and tablet standards), none addressing copper status; a completed, reviewed negative. A second query broadened to the class level, "serotonin 1B/1D receptor agonist copper ceruloplasmin trace mineral," returned five results, all general serotonin-receptor pharmacology or other triptans' clinical-development literature (frovatriptan, zolmitriptan, an IS-159 peptide 5-HT1 agonist), none touching copper or ceruloplasmin; this closes off the Tier C class-extrapolation route for copper as well, matching what a companion zolmitriptan repair pass found independently. PubMed search-listing, Europe PMC REST API, Semantic Scholar API, and the OpenAlex search endpoint (as distinct from its single-record lookup, used successfully elsewhere in this pass): each returned HTTP 429 rate-limit responses or, per the proxy status diagnostic checked at the start of this pass, HTTP 403 gateway policy denials recorded earlier in this session against pubmed.ncbi.nlm.nih.gov, www.ebi.ac.uk, and api.semanticscholar.org specifically. WebSearch: session budget already exhausted (0 of 200 remaining) before this pass began. A residual tooling-limited component remains narrower than before this pass; a future revision with working access to PubMed, Europe PMC, and Semantic Scholar should still re-check.

Iron

Not graded — disclosed evidence gap

See study details

No eletriptan-specific or defensible class-level evidence, and no circulating claim to rebut, reconfirmed on a 2026-10-01 repair pass.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Both conditions for ungraded remain met after this repair pass: no Tier B/C evidence was located, and no circulating claim naming eletriptan or triptans and iron status was found. No present Step 2 mechanism (no GI mucosal injury, no documented effect on iron-transporter activity, no induced GI bleeding risk distinct from the labeled GI-vasospasm warning covered under Oxygen delivery/utilization above) implicates iron for this drug specifically.

Channels tried, repair pass 2026-10-01

Crossref API: query "eletriptan iron hemoglobin anemia" returned five results, all general iron-deficiency-anemia or hemoglobin-supplementation studies in unrelated populations (infants, children, obesity-anemia research), with no eletriptan or triptan connection in any title or abstract; a completed, reviewed negative. PubMed, Europe PMC REST API, Semantic Scholar API, and the OpenAlex search endpoint: HTTP 429 or gateway-level HTTP 403 (per the proxy status diagnostic) on every attempt this pass, so no independent class-wide iron query could be completed the way it was for copper; this remains the narrower, genuinely tooling-limited piece of this entry. WebSearch: session budget already exhausted before this pass began. A future revision should re-attempt a class-wide triptan-plus-iron query once PubMed or Europe PMC access is restored.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No eletriptan- or triptan-class evidence passes the cohort test, and no circulating claim to rebut, reconfirmed on a 2026-10-01 repair pass.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: No Tier A/B eletriptan-specific microbiome data was found. A theoretical pathway connecting serotonergic signaling to gut microbiome composition does exist in the broader literature (enterochromaffin-cell serotonin production, gut-brain-axis research), but every source located in this review studies endogenous or dietary serotonin/tryptophan and the microbiome, not any triptan drug - this fails the Hard Rule 6 cohort/class test entirely, since no triptan-class member appears in any located study's cohort, so it does not even qualify as Tier C class extrapolation. No circulating claim specifically naming eletriptan or triptans and the gut microbiome was found. This entry is distinct from the labeled gastrointestinal-vascular-ischemia (vasospasm) risk disclosed under Oxygen delivery/utilization above, which is a vascular, not a microbiome, phenomenon - see the Overlap map.

Channels tried, repair pass 2026-10-01

Crossref API: query "eletriptan gut microbiome" returned five results, all general gut-microbiome research (journal overviews, aging/inflammation reviews, a textbook chapter) with no eletriptan or any triptan named in any title; a completed, reviewed negative. A follow-up class-wide query, "5-HT1B 1D receptor agonist gut microbiome serotonin enterochromaffin," was attempted to test the Tier C extrapolation route the way the copper entry's class-wide query succeeded, but returned HTTP 429 before results could be reviewed, so that specific extrapolation route is not yet closed off the way copper's is; this is the one piece of this entry disclosed as tooling-limited rather than a completed negative. PubMed, Europe PMC REST API, Semantic Scholar API, and the OpenAlex search endpoint: HTTP 429 or gateway-level HTTP 403 on every attempt this pass. WebSearch: session budget already exhausted before this pass began. A future revision should re-attempt the class-wide serotonin-receptor-agonist-plus-microbiome query specifically, along with PubMed and Europe PMC.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production - migraine-disease context flag, not an eletriptan effect

Yellow — Low

See study details

Reduced cerebral ATP/energy metabolism is proposed as part of migraine pathophysiology; not described anywhere as an eletriptan effect.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: As with the two entries above, the cited review contains no drug-level (triptan) ATP or energy-metabolism data.
  • At-risk subgroups: Migraineurs generally, not an eletriptan-specific subgroup.
  • Counter-evidence on record: No eletriptan-specific ATP or cellular-energy study was located.

Regulatory status

Not addressed in the RELPAX label.

Population evidence

Same 2025 narrative review: lactate elevation (a marker of impaired oxidative ATP production) correlated with headache severity, and ion-channel-driven disruption of neuronal energy metabolism is described as a feature of migraine itself.

Mechanism

Disease-intrinsic per above; no mitochondrial/ATP-pathway mechanism was identified for eletriptan - it is hepatically cleared via CYP3A4 with no mitochondrial toxicity data of any kind located for this drug.

Counter-evidence held on record

Kept as an independent entry from Mitochondrial burden and Oxidative stress per Hard Rule 7, even though all three rest on the same single source - disclosed in the Overlap map below. No supplementation dose is recommended on this basis.

Oxygen delivery/utilization - drug's own vasoconstrictive mechanism, upgraded on repair pass

Yellow — Low

See study details

Two eletriptan-specific published case reports describe reversible cerebral vasoconstriction syndrome, one progressing to stroke, and a companion-triptan human study shows the same 5-HT1B/1D vasoconstrictive mechanism transiently reduces peripheral muscle oxygen storage; this is a mechanism clarification of eletriptan's own intended pharmacology, not a nutrient-mediated oxygen-delivery deficiency.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Key negative/null findings: None identified for eletriptan specifically in the channels reached this pass. Companion triptan dossiers in this project found drug-specific bounding or null data for their own molecules (for example, rizatriptan: no significant change in cerebral blood flow velocity during migraine attacks), but no equivalent eletriptan-specific null study was located here; this is disclosed as an evidence gap within the entry, not treated as a null result.
  • At-risk subgroups: Per the FDA label: patients with risk factors for coronary artery disease, Prinzmetal's angina, peripheral vascular disease, ischemic bowel disease, or Raynaud's syndrome. Per the two case reports: patients on concomitant serotonergic or migraine-preventive medications (fluoxetine, amitriptyline, erenumab), which may compound serotonergic or vasoconstrictive burden - a drug-interaction and cardiovascular-safety signal, not a nutrient-status one.
  • Counter-evidence on record: Both located case reports involve eletriptan in combination with another serotonergic or migraine-preventive drug, not eletriptan monotherapy, so neither can isolate eletriptan's independent contribution to the reported event; this confounding limitation is disclosed rather than omitted. A dedicated eletriptan-plus-vasoconstriction Crossref query surfaced only these two case reports and no larger eletriptan-specific cohort study, bounding the strength of this evidence to case-report level.

Regulatory status

FDA label: RELPAX "may cause coronary artery vasospasm (Prinzmetal's angina), even in patients without a history of CAD," and "may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction... and Raynaud's syndrome" (Warnings and Precautions).

Population evidence

Tier B, eletriptan-specific (case reports, opened directly via Crossref, full bibliographic record confirmed): "Reversible severe cerebral vasoconstriction syndrome leading to stroke: case report," Reactions Weekly 2016;1583(1):441, concerning eletriptan combined with fluoxetine, DOI 10.1007/s40278-016-13004-3. "Anxiety issues and reversible cerebral vasoconstriction syndrome: case report," Reactions Weekly 2022;1905(1):37, concerning amitriptyline, eletriptan, and erenumab combined, DOI 10.1007/s40278-022-14427-4. Both are multi-drug case reports, not eletriptan monotherapy. Tier C, class extrapolation (sumatriptan, not eletriptan, in the cohort): Boska MD, Welch KMA, Schultz L, Nelson JA. Effects of the Anti-Migraine Drug Sumatriptan on Muscle Energy Metabolism: Relationship to Side-Effects. Cephalalgia 2000;20(1):39-44, DOI 10.1046/j.1468-2982.2000.00009.x, opened directly via an OpenAlex single-record (per-DOI) lookup after the OpenAlex and Europe PMC search endpoints were rate-limited. In migraine patients given subcutaneous sumatriptan, 31P magnetic resonance spectroscopy showed reduced oxygen storage in peripheral skeletal muscle and transient mitochondrial-function reduction, attributed to mild vasoconstriction and correlated with limb heaviness and muscle-ache side effects, more pronounced in patients with migraine with aura.

Mechanism

Named and explicit: 5-HT1B/1D receptor-mediated vasoconstriction, the same mechanism that produces eletriptan's therapeutic effect on cranial vessels and its labeled coronary/non-coronary vasospasm warnings, reported in two case reports as severe enough to cause reversible cerebral vasoconstriction syndrome and, in one case, stroke.

Counter-evidence held on record

This is eletriptan's own intended vasoconstrictive mechanism, not anemia, hypoxia, or a nutrient-mediated oxygen-carrying deficiency, per Hard Rule 2. The two case reports describe serious but rare events in patients on concomitant serotonergic or migraine-preventive medications, not typical-dose monotherapy risk, and must not be read as quantifying how often this occurs. No iron, B12, or other hematologic supplementation is indicated by this finding.

How the body handles this medication

Metabolism
Primarily hepatic via CYP3A4; N-demethylated metabolite is the only known active metabolite (10-20% of parent exposure, half-life ~13h). Eletriptan is a CYP3A4 substrate, not an inducer or inhibitor, at recommended doses.FDA RELPAX prescribing information, Clinical Pharmacology
Elimination
Terminal half-life ~4 hours (5.7 hours in elderly subjects, up from 4.4 hours); nonrenal clearance accounts for about 90% of total clearance; renal clearance is only ~3.9 L/h.FDA RELPAX prescribing information, Clinical Pharmacology
Renal impairment
"No significant change in clearance observed in subjects with mild, moderate or severe renal impairment." No documented effect on renal tubular handling of water or electrolytes.FDA RELPAX prescribing information, Clinical Pharmacology
Hepatic impairment
Mild/moderate impairment: AUC +34%, Cmax +18%, increased half-life. Severe impairment not evaluated; RELPAX "is not recommended for use in patients with severe hepatic impairment."FDA RELPAX prescribing information, Clinical Pharmacology / Warnings
Absorption
Oral bioavailability ~50%; median Tmax ~2.0 hours in migraine patients. A high-fat meal increases AUC and Cmax by approximately 20-30% (slower/greater absorption, not a malabsorption or chelation mechanism). No gastric-pH-dependent or mineral-chelation interaction is documented.FDA RELPAX prescribing information, Clinical Pharmacology
Dosing pattern
Acute, as-needed treatment of a migraine attack (not chronic daily maintenance dosing); labeled maximum of two doses in 24 hours. This intermittent-exposure pattern limits the plausibility of any cumulative nutrient-depletion mechanism relative to a daily chronic medication.FDA RELPAX prescribing information, Dosage and Administration
All references used above
  1. RELPAX (eletriptan hydrobromide) Tablets - full prescribing information — FDA regulatory label, Pfizer/Viatris, document 021016s021s023s024s027, 2013 revision. Opened and quoted directly for Clinical Pharmacology, Drug Interactions, Warnings and Precautions, and Adverse Reactions.
  2. DailyMed - RELPAX (eletriptan hydrobromide) tablet, film coated — National Library of Medicine, current label listing. Used to confirm current label identity.
  3. WHO Collaborating Centre for Drug Statistics Methodology - ATC/DDD Index, N02CC06 — Opened directly. Confirms: "N02CC06 | eletriptan | 40 | mg | O", class "Selective serotonin (5HT1) agonists."
  4. American Migraine Foundation - "Magnesium and Migraine" — Consumer-facing clinical resource. Opened and quoted directly. Disease-association evidence only.Cohort excluded this drug: discusses migraine generally, not eletriptan or any specific triptan. Used only as Step 7 "context flag" evidence, not as drug-attribution evidence.
  5. "Evaluating the Role of Coenzyme Q10 in Migraine Therapy - A Narrative Review" — Antioxidants (MDPI), 2025. Opened and quoted directly for mitochondrial/oxidative-stress pathophysiology of migraine.Cohort excluded this drug: narrative review of migraine pathophysiology and CoQ10 supplementation; explicitly states no triptan/eletriptan mechanistic data is discussed. Used only as Step 7 "context flag" evidence.
  6. PBA Health - "Drug-Induced Nutrient Deficiencies" — Consumer resource, checked for the Step 6 circulating-claim audit. Opened directly; confirmed it covers ten drug classes and does not mention triptans or migraine medications.
  7. Drugs.com - Eletriptan/Relpax Drug Interactions Checker — Opened directly. Lists melatonin, vitamin B12, and vitamin D3 among "frequently checked" pairings with no severity or mechanism data provided by the tool for those specific pairings; not used as evidence for any graded entry.
  8. PubMed search-listing - query "eletriptan AND magnesium" — Opened directly; 14 results returned, none specific to eletriptan and magnesium status (general migraine-treatment reviews only).Could not open: later queries in this same session for "eletriptan" plus mitochondria, oxidative stress, iron, copper, and microbiome terms returned a reCAPTCHA/bot-verification page instead of results. Access-blocked, not a confirmed null result. Re-attempted on the 2026-10-01 repair pass: still blocked, now confirmed via the proxy status diagnostic as a gateway-level HTTP 403 policy denial against pubmed.ncbi.nlm.nih.gov recorded earlier in this session, not merely a bot-verification page.
  9. Europe PMC REST API (search endpoint) — Queried multiple times across this session for eletriptan combined with mitochondria, oxidative stress, iron, copper, microbiome, and ATP terms.Could not open: every attempt returned HTTP 429 (rate-limited) despite retries spaced 60-180 seconds apart across the session. Disclosed as a tooling-access limitation for this review, not a confirmed absence of literature. Re-attempted on the 2026-10-01 repair pass for gut microbiome: still blocked (HTTP 429/403).
  10. Semantic Scholar Graph API (paper search endpoint) — Queried for eletriptan combined with mitochondria/iron/copper/microbiome/oxidative-stress terms.Could not open: returned HTTP 429 from the target server. Disclosed as a tooling-access limitation, not a confirmed absence of literature. Re-attempted on the 2026-10-01 repair pass: still blocked (HTTP 429).
  11. OpenAlex Works API (search endpoint) — Queried for eletriptan combined with the same category terms.Could not open: returned HTTP 429 from the target server. Disclosed as a tooling-access limitation, not a confirmed absence of literature. Re-attempted on the 2026-10-01 repair pass: the search endpoint remained blocked (HTTP 429), but the per-DOI single-record lookup endpoint (below) succeeded and is used as a primary source.
  12. OpenAlex Works API (single-record, per-DOI lookup) — Repair pass 2026-10-01. Opened directly and succeeded where the search endpoint did not: https://api.openalex.org/works/doi:10.1046/j.1468-2982.2000.00009.x returned full metadata and abstract for Boska MD, Welch KMA, Schultz L, Nelson JA, "Effects of the Anti-Migraine Drug Sumatriptan on Muscle Energy Metabolism: Relationship to Side-Effects," Cephalalgia 2000;20(1):39-44, closed access. Used as Tier C class-extrapolation evidence under Oxygen delivery/utilization (sumatriptan, not eletriptan, was in this study's cohort).
  13. Crossref API - query "eletriptan copper" — Repair pass 2026-10-01. Opened directly; five results, all USP pharmacopeial monographs for eletriptan hydrobromide, none addressing copper status. Completed negative.
  14. Crossref API - query "serotonin 1B/1D receptor agonist copper ceruloplasmin trace mineral" — Repair pass 2026-10-01. Opened directly; five results, all general serotonin-receptor pharmacology or other triptans' clinical literature (frovatriptan, zolmitriptan, an IS-159 peptide 5-HT1 agonist), none addressing copper or ceruloplasmin. Completed negative, closing off Tier C class extrapolation for copper.
  15. Crossref API - query "eletriptan iron hemoglobin anemia" — Repair pass 2026-10-01. Opened directly; five results, all general iron-deficiency-anemia/hemoglobin-supplementation studies in unrelated populations (infants, children, obesity-anemia research), none naming eletriptan or any triptan. Completed negative.
  16. Crossref API - query "eletriptan gut microbiome" — Repair pass 2026-10-01. Opened directly; five results, all general gut-microbiome research (journal overviews, an aging/inflammation review, a textbook chapter), none naming eletriptan or any triptan. Completed negative at the drug-specific level.
  17. Crossref API - query "5-HT1B/1D receptor agonist gut microbiome serotonin enterochromaffin" (class-level) — Repair pass 2026-10-01. Attempted to close off the Tier C class-extrapolation route for Gut microbiome risk the way the copper query did; returned HTTP 429 before results could be reviewed.Could not open: HTTP 429. Disclosed as a tooling-access limitation specific to this one class-level query; unlike copper, this extrapolation route for gut microbiome risk is not yet closed off and should be re-attempted in a future revision.
  18. Crossref API - query "eletriptan coronary vasoconstriction peripheral blood flow" — Repair pass 2026-10-01. Opened directly; five results, two naming eletriptan specifically (case-report digests, both cited above under Oxygen delivery/utilization).
  19. "Reversible severe cerebral vasoconstriction syndrome leading to stroke: case report" (eletriptan/fluoxetine) — Repair pass 2026-10-01. Reactions Weekly 2016;1583(1):441. Opened directly via the Crossref record for its DOI, which returned the full subtitle/descriptive text quoted above; full publisher text could not be reached this pass (HTTP 429 on retry). Cited as Tier B, eletriptan named specifically, but as a multi-drug case report (eletriptan plus fluoxetine), not monotherapy.
  20. "Anxiety issues and reversible cerebral vasoconstriction syndrome: case report" (amitriptyline/eletriptan/erenumab) — Repair pass 2026-10-01. Reactions Weekly 2022;1905(1):37. Opened directly via the Crossref record for its DOI, which returned the full subtitle/descriptive text quoted above; full publisher text could not be reached this pass (HTTP 429 on retry). Cited as Tier B, eletriptan named specifically, but as a multi-drug case report (amitriptyline, eletriptan, and erenumab together), not monotherapy.
  21. PubMed Central (PMC) — Attempted to open a magnesium/migraine review article directly for primary-source quotation.Could not open: returned a reCAPTCHA/bot-verification page. Disclosed as a tooling-access limitation.
  22. Proxy status diagnostic (agent-proxy gateway) — Repair pass 2026-10-01. Opened directly at the start of this pass; confirmed WebSearch budget already at 0 of 200 remaining, and logged recent gateway-level HTTP 403 "policy denial or upstream failure" rejections against pubmed.ncbi.nlm.nih.gov, www.ebi.ac.uk, api.crossref.org, api.semanticscholar.org, api.openalex.org, eutils.ncbi.nlm.nih.gov, and dailymed.nlm.nih.gov earlier in this session, corroborating that the HTTP 429/403 responses hit during this pass reflect organization-level network policy, not a per-request fluke.
  23. WebSearch (general web, session tool) — Approximately ten queries run across magnesium, serotonin/tryptophan, mitochondrial, oxidative-stress, iron/copper, gut-microbiome, hyponatremia/SIADH, coronary-vasoconstriction, and drug-nutrient-depletion-handbook topics. No eletriptan-specific hits emerged for mitochondrial burden, oxidative stress, copper, iron, or gut microbiome beyond what is cited above.Tool's session-wide budget (shared across concurrently running companion dossiers in this environment) was exhausted at 200 of 200 calls partway through this review, blocking further general-web queries for the remaining unsearched phrasings. Confirmed still at 0 of 200 remaining on the 2026-10-01 repair pass; no WebSearch calls were available for this pass.